New ADCs bring new questions in EGFR NSCLC and beyond

Antibody drug conjugates (ADCs) represent one of the fastest growing therapeutic drug classes in solid tumor oncology. The ability to combine highly potent payload moieties with monoclonal antibodies selective for tumor specific antigens has shifted our approach in treating patients with multiple different tumor types, including non-small cell lung cancer (NSCLC). Currently three ADCs in NSCLC have received accelerated approval or breakthrough therapy designation from the FDA, including trastuzumab deruxtecan (T-DXd) for HER2-mutated NSCLC, telisotuzumab vedotin (Teliso-V) for NSCLC with MET overexpression, and patritumab deruxtecan (HER3-DXd) for EGFR-mutated NSCLC.